Relay Therapeutics, Inc. (RLAY) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Relay Therapeutics is a clinical-stage precision medicine company utilizing its Dynamo® platform to discover small molecule therapeutics for oncology and genetic diseases. The company has no products approved for commercial sale and has incurred significant operating losses since inception. As of March 31, 2025, the company had an accumulated deficit of $1.8 billion.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $7.7 million | $10.0 million |
| Net Loss | $(77.1) million | $(81.4) million |
| Net Loss Per Share (Basic & Diluted) | $(0.46) | $(0.62) |
| Operating Expenses | $92.5 million | $100.4 million |
| Cash, Cash Equivalents, and Investments | $710.4 million | $779.2 million (Dec 31, 2024) |
| Net Cash Used in Operating Activities | $(73.2) million | $(50.3) million |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by $2.3 million (23%) compared to Q1 2024. This was driven by the termination of the Genentech collaboration agreement effective January 7, 2025, which previously contributed $10.0 million in revenue in Q1 2024. Q1 2025 revenue consisted entirely of $7.7 million recognized from a new exclusive license agreement with Elevar Therapeutics.
- Expense Reduction: Total operating expenses decreased by $7.8 million. Research and Development (R&D) expenses dropped $8.6 million to $73.8 million, primarily due to strategic streamlining of the research organization. General and Administrative (G&A) expenses decreased $1.1 million to $18.7 million.
- Improved Net Loss: Net loss improved by $4.3 million to $77.1 million, reflecting the reduction in operating expenses despite lower revenue.
- Contingent Consideration: The change in fair value of contingent consideration liability was $0 in Q1 2025, compared to a $1.8 million gain in Q1 2024. The liability was fully resolved in late 2024.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing cash, cash equivalents, and investments of $710.4 million are sufficient to fund operations and capital expenditures into 2029. No new financing was raised in Q1 2025.
- Clinical Progress:
- RLY-2608 (Lead Candidate): A Phase 2 trial for PIK3CA-related overgrowth spectrum (PROS) was initiated in Q1 2025. The company plans to initiate a Phase 3 registrational study (ReDiscover-2) for breast cancer.
- Collaborations: The Genentech agreement was terminated without cause, ending future milestone payments. The Elevar agreement for lirafugratinib (RLY-4008) was executed in December 2024, with $7.7 million recognized in Q1 2025.
- Key Risks:
- Capital Requirements: The company expects to incur significant losses for the foreseeable future and will need substantial additional funding to complete development and commercialization.
- Clinical Uncertainty: No large-scale pivotal trials have been completed. Early data is not predictive of later-stage results.
- Third-Party Reliance: The company relies on third parties for clinical trials and manufacturing. Disruptions could delay development.
- Legal Proceedings: A derivative complaint was filed in December 2024 alleging excessive director compensation; the outcome is uncertain.
Investor Verification Checklist
- Verify the timeline and design of the upcoming Phase 3 ReDiscover-2 trial for RLY-2608 in breast cancer.
- Confirm the status of the Elevar Therapeutics collaboration and the potential for future milestone payments (up to $495 million).
- Monitor cash burn rates against the stated runway into 2029, particularly given the termination of the Genentech revenue stream.
- Review the progress of the derivative lawsuit filed by David Hayes regarding director compensation.
- Assess the impact of the Genentech termination on the company's overall partnership strategy and future revenue diversification.